<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gestational diabetes mellitus: Glucose management and maternal prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gestational diabetes mellitus: Glucose management and maternal prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gestational diabetes mellitus: Glucose management and maternal prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Celeste Durnwald, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Erika F Werner, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of gestational diabetes mellitus (GDM) can improve pregnancy outcome. Many patients can achieve glucose target levels with nutritional therapy and moderate exercise alone, but up to 30 percent will require pharmacotherapy [
         <a href="#rid1">
          1
         </a>
         ]. Even patients with mildly elevated glucose levels who do not meet standard criteria for GDM may have more favorable pregnancy outcomes if treated since the relationship between glucose levels and adverse pregnancy outcomes such as macrosomia exists continuously across the spectrum of increasing glucose levels [
         <a href="#rid2">
          2-9
         </a>
         ].
        </p>
        <p>
         Glucose management in patients with GDM is reviewed here. Screening, diagnosis, and obstetric management are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6797.html" rel="external">
          "Gestational diabetes mellitus: Screening, diagnosis, and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">
          "Gestational diabetes mellitus: Obstetric issues and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          RATIONALE FOR TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         GDM is treated to minimize maternal and neonatal morbidity. In a United States Preventive Services Task Force (USPSTF) meta-analysis of randomized trials, compared with no treatment, treatment (which generally included nutritional therapy, self-blood glucose monitoring, administration of insulin when target blood glucose concentrations were not met with diet alone) resulted in reductions in [
         <a href="#rid10">
          10,11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Newborn birth injury (absolute risk difference 0.2 percent; OR 0.33, 95% CI 0.11-0.99)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shoulder dystocia (absolute risk difference 1.3 percent; RR 0.42, 95% CI 0.23-0.77)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrosomia &gt;4000 g (absolute risk difference 8.9 percent; RR 0.53, 95% CI 0.41-0.68)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large for gestational age (absolute risk difference 8.4 percent; RR 0.56, 95% CI 0.47-0.66)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neonatal intensive care unit admission (absolute risk difference 2.0 percent; RR 0.73, 95% CI 0.53-0.99)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary cesarean birth (absolute risk difference 5.3 percent; RR 0.70, 95% CI 0.54-0.91)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preeclampsia (absolute risk difference 1 percent; RR 0.60, 95% CI 0.35-1.01 for five trials in Very High Human Development Index Countries)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preterm birth (absolute risk difference 2.3 percent; RR 0.75, 95% CI 0.56-1.01)
        </p>
        <p>
        </p>
        <p>
         There were no significant reductions in hypertensive disorders of pregnancy, gestational hypertension, need for total or emergency cesarean delivery, induction of labor, maternal birth trauma, perinatal mortality, macrosomia &gt;4500 g, respiratory distress syndrome, any neonatal hypoglycemia or hyperbilirubinemia. In contrast to a prior USPSTF meta-analysis, the more recent analysis found no reduction in preeclampsia when a trial from a non-Very High Human Development Index Country was included (RR 0.99, 95% CI 0.46-2.16).
        </p>
        <p>
         For long-term outcomes, children had no significant reduction in childhood overweight (BMI ≥85th percentile), obesity (BMI ≥95th percentile), metabolic impairment or type 2 diabetes, and mothers had no significant reduction in maternal obesity (BMI ≥30), metabolic impairment (impaired fasting glucose), metabolic syndrome, or type 2 diabetes at 5 to 10 years.
        </p>
        <p>
         There were no significant maternal or neonatal harms from treatment of GDM.
        </p>
        <p>
         Some authors have suggested that avoiding maternal obesity and excessive gestational weight gain may be more important than detecting and treating GDM because maternal weight may be more closely related to adverse outcomes, particularly fetal overgrowth, than glucose intolerance [
         <a href="#rid12">
          12
         </a>
         ]. However, data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study refute this hypothesis. In HAPO, both obesity and GDM (International Association of Diabetes and Pregnancy Study Groups criteria) were independently predictive of macrosomia, preeclampsia, primary cesarean birth, and neonatal adiposity [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Few studies have evaluated the long-term effects of maternal treatment of GDM on offspring. Follow-up data from 500 offspring of mothers enrolled in a randomized trial of treatment versus no treatment of mild GDM showed that maternal treatment did not reduce late adverse metabolic outcomes (eg, obesity, glucose intolerance) in offspring at age 5 to 10 years [
         <a href="#rid13">
          13
         </a>
         ]. This finding may reflect lack of a true treatment effect, inadequate treatment of hyperglycemia during pregnancy, the mildness of the glucose intolerance, or inadequate power to show modest differences in outcome because of the low prevalence of these disorders prior to puberty, and the small numbers of study participants. (Mild GDM was defined as fasting plasma glucose &lt;95 mg/dL [5.3 mmol/L] and two of three timed measurements that exceeded established thresholds [one hour, 180 mg/dL [10 mmol/L]; two hours, 155 mg/dL [8.6 mmol/L]; three hours, 140 mg/dL [7.8 mmol/L]).
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          MEDICAL NUTRITIONAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medical nutritional therapy is the process by which the dietary plan is tailored for patients with diabetes, based on medical, lifestyle, and personal factors. Patients with GDM should receive medical nutritional counseling by a registered dietitian (when possible) upon diagnosis and be placed on an appropriate diet. The goals are to [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Achieve normoglycemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevent ketosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide adequate nutrition
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide adequate gestational weight gain based on maternal body mass index (BMI)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contribute to fetal well-being
        </p>
        <p>
        </p>
        <p>
         Most patients (up to 85 percent) with GDM based on Carpenter and Coustan criteria can achieve target glucose levels with lifestyle modification alone [
         <a href="#rid3">
          3,15
         </a>
         ]. A detailed review of medical nutritional therapy for individuals with diabetes can be found separately. (See
         <a class="medical medical_review" href="/z/d/html/1765.html" rel="external">
          "Nutritional considerations in type 1 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         The specific diet that achieves optimum maternal and newborn outcomes in GDM is unclear [
         <a href="#rid16">
          16-18
         </a>
         ]. A key simple, achievable intervention is to emphasize the benefits of elimination, or at least reduction, of consumption of sugar-sweetened beverages (eg, soft drinks, fruit drinks) and encourage drinking water instead. Noncaloric sweeteners may be used in moderation. Traditionally, restricting carbohydrate intake (particularly simple carbohydrates) has been favored because it appears to reduce postprandial hyperglycemia [
         <a href="#rid19">
          19
         </a>
         ] and fetal overgrowth [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         In a systematic review of randomized trials comparing a variety of dietary interventions (eg, low glycemic index, DASH, low carbohydrate, energy restriction, soy protein, fat modification, ethnic, high fiber) with conventional dietary recommendations for patients with GDM (18 trials, 1151 participants), dietary intervention overall reduced fasting and postprandial glucose levels (fasting: -4.07 mg/dL, 95% CI -7.58 to -0.57; postprandial -7.78 mg/dL, 95% CI -12.27 to -3.29), need for medication (relative risk [RR] 0.65, 95% CI 0.47-0.88), birth weight (-170.62 g, 95% CI -333.64 to -7.60), and macrosomia (RR 0.49, 95% CI 0.27-0.88) [
         <a href="#rid17">
          17
         </a>
         ]. When analyzed by diet subtype, low glycemic index, DASH, low carbohydrate, and ethnicity-based diets had beneficial effects on maternal glucose levels. A limitation of the analysis was that all of the trials had small sample sizes.
        </p>
        <p>
         Probiotics and high fiber diets do not appear to improve glycemic control [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H36548474">
         <span class="h2">
          Meal plan
         </span>
         <span class="headingEndMark">
          —
         </span>
         A typical meal plan for patients with GDM includes three small- to moderate-sized meals and two to four snacks. Ongoing adjustment of the meal plan is based upon results of self-glucose monitoring, appetite, and weight-gain patterns, as well as consideration for maternal dietary preferences and work, leisure, and exercise schedules.
        </p>
        <p>
         Close follow-up is important to ensure nutritional adequacy. Individual assessment and self-blood glucose monitoring are used to determine and modify specific nutrition/food recommendations. If insulin therapy is added to nutritional therapy, a primary goal is to maintain carbohydrate consistency at meals and snacks to facilitate insulin adjustments.
        </p>
        <p class="headingAnchor" id="H2240288023">
         <span class="h3">
          Calories
         </span>
         <span class="headingEndMark">
          —
         </span>
         The caloric requirements of patients with GDM are the same as those for pregnant patients without GDM [
         <a href="#rid24">
          24
         </a>
         ]. For individuals with a prepregnancy BMI in the healthy range, caloric requirements in the first trimester are the same as before pregnancy and generally increase by 340 calories per day in the second trimester and 452 calories per day in the third trimester [
         <a href="#rid25">
          25
         </a>
         ]. Individuals who are underweight, overweight, or obese should work with a registered dietician to determine their specific caloric requirements. (See
         <a class="medical medical_review" href="/z/d/html/441.html" rel="external">
          "Gestational weight gain"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1663664966">
         <span class="h3">
          Carbohydrate intake
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the caloric needs are calculated, carbohydrate intake is determined as it is the primary nutrient affecting postprandial glucose levels. The total amount of carbohydrate consumed, the distribution of carbohydrate intake over meals and snacks, and the type of carbohydrate consumed can be manipulated to blunt postprandial hyperglycemia.
        </p>
        <p>
         Dietary Reference Intakes (DRI) for all pregnant people is a minimum of 175 g of carbohydrate per day and 28 g of fiber [
         <a href="#rid24">
          24
         </a>
         ]. There is sparse evidence from randomized trials as to the ideal carbohydrate intake for individuals with GDM. We limit carbohydrate intake to 40 percent of total calories while ensuring that ketonuria does not ensue [
         <a href="#rid26">
          26,27
         </a>
         ]. Adequately powered studies are needed to evaluate the effect of various dietary interventions on perinatal outcomes in GDM.
        </p>
        <p>
         Many patients will need individual adjustment of the amount of carbohydrate by 15 to 30 g at each meal, depending on their postprandial glucose levels, which are directly dependent upon the carbohydrate content of the meal or snack [
         <a href="#rid28">
          28
         </a>
         ]. The postprandial glucose rise can be blunted if the diet is carbohydrate restricted. However, reducing carbohydrates to decrease postprandial glucose levels may lead to higher consumption of fat, which may have adverse effects on maternal insulin resistance and fetal body composition.
        </p>
        <p>
         In a meta-analysis of randomized trials of dietary intervention in patients with GDM, low carbohydrate diets had a favorable effect on postprandial blood glucose concentrations and significantly lowered the need for insulin therapy but did not affect other maternal or newborn outcomes (eg, macrosomia, cesarean birth, gestational weight gain), although the data were insufficient to detect small or moderate statistical differences in obstetric outcomes between the patient groups [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1766.html" rel="external">
          "Nutritional considerations in type 2 diabetes mellitus", section on 'Glycemic index and glycemic load'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3686230906">
         <span class="h3">
          Protein and fat intake
         </span>
         <span class="headingEndMark">
          —
         </span>
         The remaining calories come from protein (20 percent of total calories or approximately 71 g per day [
         <a href="#rid24">
          24
         </a>
         ]) and fats (40 percent of total calories; saturated fat intake should be &lt;7 percent of total calories). Protein intake should be distributed throughout the day and included in all meals and snacks to promote satiety, slow the absorption of carbohydrates into the bloodstream, and provide adequate calories.
        </p>
        <p>
         A bedtime high-protein snack is recommended to prevent accelerated (ie, starvation) ketosis overnight and maintain fasting glucose levels within the target range.
        </p>
        <p class="headingAnchor" id="H3033589834">
         <span class="h2">
          Gestational weight gain/loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         After prescribing the diet, it is important to pay attention to subsequent changes in weight. In a retrospective cohort study including over 31,000 patients with GDM, those with appropriate gestational weight gain  (
         <a class="graphic graphic_table graphicRef75820" href="/z/d/graphic/75820.html" rel="external">
          table 1
         </a>
         ) had optimal outcomes, while excessive gestational weight gain was associated with a significantly increased risk of having a large for gestational age newborn, preterm birth, and cesarean birth [
         <a href="#rid30">
          30
         </a>
         ]. Although suboptimal weight gain increased the likelihood of avoiding pharmacotherapy of GDM and decreased the likelihood of having a large for gestational age newborn, there were also more small for gestational age newborns in this group (7.3 versus 5.6 percent). The data in this study were not corrected for potential confounders, such as smoking. (See
         <a class="medical medical_review" href="/z/d/html/433.html" rel="external">
          "Obesity in pregnancy: Complications and maternal management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/441.html" rel="external">
          "Gestational weight gain", section on 'Recommendations for gestational weight gain'
         </a>
         .)
        </p>
        <p>
         Some patients experience minimal weight loss (one to five pounds) or weight stabilization for the first few weeks after beginning nutritional therapy, which should be evaluated in the overall context of gestational weight gain and ongoing surveillance of weight gain in the weeks thereafter. Weight loss is generally not recommended during pregnancy, although controversy exists regarding this recommendation for patients with obesity, especially class II or III. For pregnant people with obesity, a modest energy restriction of 30 percent below the DRI for pregnant people (175 g carbohydrate, 71 g protein, 28 g fiber [
         <a href="#rid24">
          24
         </a>
         ]) can often be achieved while meeting gestational weight gain recommendations and without causing ketosis [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/441.html" rel="external">
          "Gestational weight gain", section on 'Recommendations for gestational weight gain'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29677932">
         <span class="h1">
          EXERCISE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adults with diabetes are encouraged to perform 30 to 60 minutes of moderate-intensity aerobic activity (40 to 60 percent maximal oxygen uptake [VO
         <sub>
          2
         </sub>
         max]) on most days of the week (at least 150 minutes of moderate-intensity aerobic exercise per week). A program of moderate exercise is recommended as part of the treatment plan for patients with diabetes as long as they have no medical or obstetric contraindications to this level of physical activity. Exercise that increases muscle mass, including aerobic, resistance, and circuit training, appears to improve glucose management, primarily from increased tissue sensitivity to insulin. As a result, exercise can reduce both fasting and postprandial blood glucose concentrations and, in some patients with GDM, the need for insulin may be obviated [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/412.html" rel="external">
          "Exercise during pregnancy and the postpartum period"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1777.html" rel="external">
          "Exercise guidance in adults with diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          GLUCOSE MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should self-monitor their glucose concentrations. Glucose meters measure capillary blood glucose, almost all available glucose meters provide plasma equivalent values rather than whole-blood glucose values. Thus, results from most available glucose meters and venous plasma glucose measured in a laboratory should be comparable. (See
         <a class="medical medical_review" href="/z/d/html/1781.html" rel="external">
          "Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1539779042">
         <span class="h2">
          Intermittent self-monitoring of blood glucose
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that patients self-monitor blood glucose levels [
         <a href="#rid33">
          33-36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Before breakfast (ie, fasting glucose level)
         <strong>
          and
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At one
         <strong>
          or
         </strong>
         at two hours after the beginning of each meal
        </p>
        <p>
        </p>
        <p>
         Results should be recorded in a glucose log, along with dietary information. This facilitates recognition of glycemic patterns and helps to interpret results stored in the memory of glucose meters.
        </p>
        <p>
         We prefer the one-hour postprandial measurement as it corresponds more closely to the maximum insulin peak in patients using rapid-acting insulin analogs. The value of fasting plus postprandial versus preprandial measurement was suggested by a trial that randomly assigned 66 insulin-treated patients with GDM to management according to results of fasting plus postprandial monitoring (one hour after meals) or according to preprandial-only blood glucose concentrations [
         <a href="#rid37">
          37
         </a>
         ]. Postprandial monitoring had several benefits as compared with preprandial monitoring: better glycemic management (glycated hemoglobin [A1C] value 6.5 versus 8.1 percent), a lower incidence of large for gestational age newborns (12 versus 42 percent), and a lower rate of cesarean birth for cephalopelvic disproportion (12 versus 36 percent).
        </p>
        <p class="headingAnchor" id="H21910392">
         <span class="h3">
          Can the frequency of self-monitoring be reduced?
         </span>
         <span class="headingEndMark">
          —
         </span>
         When initially diagnosed with GDM, we ask patients to measure their blood glucose concentration at least four times daily, as described above (see
         <a class="local">
          'Intermittent self-monitoring of blood glucose'
         </a>
         above). Multiple daily measurements allow recognition of patients who should begin pharmacologic therapy.
        </p>
        <p>
         There is no strong evidence regarding the frequency of glucose testing, particularly in patients on nutritional therapy who consistently have glucose levels in the target range (see
         <a class="local">
          'Glucose target'
         </a>
         below) [
         <a href="#rid38">
          38,39
         </a>
         ], but decreasing the frequency of testing to every other day in specific patients with mild GDM (defined as no more than intermittent glucose elevations within 5 to 10 mg/dL [0.3 to 0.6 mmol/L] above targets), no signs of fetal overgrowth (defined as abdominal circumference (AC) &gt;75th percentile or estimated fetal weight (EFW) ≥90
         <sup>
          th
         </sup>
         percentile), and normal amniotic fluid volume (ie, no polyhydramnios), likely improves the patient's quality of life.
        </p>
        <p>
         In a randomized trial of patients with GDM on nutritional therapy who demonstrated glucose levels in the target range after one week of four times daily glucose testing, those assigned to every other day testing had similar birth weights and frequency of macrosomia as those who continued to test four times daily [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H746303549">
         <span class="h2">
          Continuous glucose monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Continuous glucose monitoring (CGM) allows determination of peak postprandial glucose levels, mean glucose level, episodes of nocturnal hyperglycemia, and percent time in range for a 24-hour period. We do not routinely use CGM in patients with GDM because of cost and it has not been proven to improve maternal or fetal outcome, but few trials have been performed. When CGM was compared with frequent self-monitoring of blood glucose in a meta-analysis of two small randomized trials, outcomes were similar for both approaches: cesarean birth (risk ratio [RR] 0.91, 95% CI 0.68-1.20), large for gestational age newborn (RR 0.67, 95% CI 0.43-1.05), neonatal hypoglycemia (RR 0.79, 95% CI 0.35-1.78) [
         <a href="#rid41">
          41
         </a>
         ]. There were no perinatal deaths. Larger trials may clarify whether the favorable trends that were observed are real.
        </p>
        <p>
         Although use of CGM has no clear advantages for most patients, it may be considered in patients who cannot consistently check fingerstick glucose levels and are willing to wear a device. In addition, some patients choose to use CGM because they want the detailed information about their glucose levels that it provides. Cost may be a barrier to use.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Glucose target
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucose targets vary among countries and the precise target for optimum maternal, fetal, and newborn outcome is not well-established [
         <a href="#rid42">
          42
         </a>
         ]. In the United States, the American Diabetes Association (ADA) and the American College of Obstetricians and Gynecologists (ACOG) recommend the following upper limits for glucose levels, with insulin therapy initiated if they are exceeded, but acknowledge that these thresholds have been extrapolated from recommendations proposed for pregnant patients with preexisting diabetes [
         <a href="#rid24">
          24,43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fasting and preprandial blood glucose concentration: &lt;95 mg/dL (5.3 mmol/L)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One-hour postprandial blood glucose concentration: &lt;140 mg/dL (7.8 mmol/L)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two-hour postprandial glucose concentration: &lt;120 mg/dL (6.7 mmol/L)
        </p>
        <p>
        </p>
        <p>
         These targets are well above the mean glucose values in pregnant people without diabetes described in a literature review of studies of the normal 24-hour glycemic profile of pregnant people [
         <a href="#rid44">
          44
         </a>
         ]. In this review, which had a total of 255 pregnant people without diabetes who were mostly in the late third trimester and without obesity, the pooled weighted mean glucose values (±1 SD) were fasting 71±8 mg/dL (3.9±0.4 mmol/L), one-hour postprandial 109±13 mg/dL (6.0±0.7 mmol/L), two-hour postprandial 99±10 mg/dL (5.5±0.6 mmol/L), and 24-hour glucose 88±10 mg/dL (4.9±0.6 mmol/L). These levels were derived from measurements on whole blood, plasma, self-monitored capillary glucose measurements, or tissue fluid (CGM). Although glucose levels in whole blood, plasma, and interstitial fluid differ, there was some consistency in the results. If two standard deviations are added to the means outlined in the systematic review, the upper limit of normal fasting glucose would be 87 mg/dL (4.8 mmol/L), the corresponding one-hour postprandial value would be 135 mg/dL (7.5 mmol/L), and the upper limit of normal two-hour value would be 119 mg/dL (6.6 mmol/L); while the fasting value is somewhat lower than the target 95 mg/dL (5.3 mmol/L), the postprandial values are not dissimilar to the targets described above.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Glycated hemoglobin
         </span>
         <span class="headingEndMark">
          —
         </span>
         A1C may be a helpful ancillary test in assessing glycemic management during pregnancy [
         <a href="#rid45">
          45,46
         </a>
         ]. It is not clear whether or how often it should be monitored in patients with GDM with glucose levels are in the target range. If measured and there is a discrepancy between the A1C and glucose values, then potential causes should be investigated. (See
         <a class="medical medical_review" href="/z/d/html/1807.html" rel="external">
          "Measurements of chronic glycemia in diabetes mellitus", section on 'Racial/ethnic differences'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1807.html" rel="external">
          "Measurements of chronic glycemia in diabetes mellitus", section on 'Unexpected or discordant values'
         </a>
         .)
        </p>
        <p>
         High-quality normative data for A1C in each trimester are not available. A1C values tend to be lower in pregnant compared with nonpregnant people [
         <a href="#rid47">
          47
         </a>
         ] because the average blood glucose concentration is approximately 20 percent lower in pregnant people, and in the first half of pregnancy, there is a rise in red cell mass and a slight increase in red blood cell turnover [
         <a href="#rid48">
          48,49
         </a>
         ]. Other factors that have been reported to affect A1C values include race (although it is not clear whether the higher A1C levels observed in Black persons compared with White persons are due to differences in glucose levels or racial differences in the glycation of hemoglobin [
         <a href="#rid50">
          50
         </a>
         ]) and iron status (chronic iron deficiency anemia increases A1C, treatment of iron deficiency anemia with iron lowers A1C). Sources of variation in A1C levels are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1807.html" rel="external">
          "Measurements of chronic glycemia in diabetes mellitus", section on 'Glycated hemoglobin (A1C)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          MONITORING FOR KETONURIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely monitor urinary ketones in pregnant people with GDM, as diabetic ketoacidosis is extremely rare in patients first diagnosed with diabetes during pregnancy [
         <a href="#rid51">
          51,52
         </a>
         ]. Episodes of physiological ketonemia and ketonuria are not uncommon in pregnancy and can occur with hypocaloric diets [
         <a href="#rid53">
          53
         </a>
         ]. Studies have reported inconsistent findings regarding a potential association between ketonuria and impaired cognitive outcome in offspring [
         <a href="#rid54">
          54-58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          PHARMACOTHERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H1557821256">
         <span class="h2">
          Goal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of pharmacotherapy is to manage glucose levels so that the majority are no higher than the upper limit of the target range, without inducing any episodes of hypoglycemia. Overly tight metabolic control (average blood glucose levels ≤86 mg/dL [4.8 mmol/L]) has no additional benefits and increases the risk for iatrogenic growth restriction [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4092405716">
         <span class="h2">
          Indications for pharmacotherapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucose levels above the target range
         </strong>
         – If glucose targets cannot be maintained by medical nutritional therapy, then pharmacotherapy should be initiated, but the degree of hyperglycemia at which the disadvantages of initiating insulin therapy are clearly outweighed by the benefits has not been definitively determined and varies among providers [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We initiate pharmacotherapy when over 30 percent of the blood glucose values in a week are above target glucose thresholds (see
         <a class="local">
          'Glucose target'
         </a>
         above). Our general approach is described in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef131228" href="/z/d/graphic/131228.html" rel="external">
          algorithm 1
         </a>
         ). In a retrospective cohort study of patients with GDM, initiating pharmacotherapy when 20 to 39 percent of glucose levels were above goal compared with ≥40 percent above goal was associated with a reductions in preterm birth (7.4 versus 15.7 percent), neonatal intensive care unit admission (4.0 versus 11.7 percent), and large for gestational age newborn (9.1 versus 21.2 percent) [
         <a href="#rid62">
          62
         </a>
         ]. Randomized trials regarding when to initiate pharmacotherapy have not been performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fetal overgrowth
         </strong>
         – Data from some randomized trials suggest that pharmacotherapy, specifically insulin, in the subgroup of patients with indirect evidence of fetal hyperinsulinemia (eg, abdominal circumference [AC] &gt;75
         <sup>
          th
         </sup>
         percentile or estimated fetal weight [EFW] ≥90
         <sup>
          th
         </sup>
         percentile on the early third-trimester sonogram) can reduce the occurrence of macrosomia and large for gestational age in newborns, even in patients with GDM who are not hyperglycemic at the time pharmacotherapy is initiated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a meta-analysis including only two trials, compared with conventional hyperglycemia-based management in patients with a broad GDM severity spectrum, initiation of pharmacotherapy based on ultrasound findings of a large AC increased the percent of patients requiring insulin treatment (34 versus 23 percent, relative risk [RR] 1.58, 95% CI 1.14-2.20) and reduced the occurrence of large for gestational age newborns (RR 0.58, 95% CI 0.34-0.99) and macrosomia (RR 0.32, 95% CI 0.11-0.95) without increasing the risk for small for gestational age newborns [
         <a href="#rid63">
          63
         </a>
         ]. Rates of pregnancy-associated hypertension and cesarean birth were similar in both groups; data on frequency of maternal hypoglycemia were not provided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Based on these and other findings, it is reasonable for patients with sonographic signs of fetal overgrowth to receive insulin to decrease the risk of large for gestational age and macrosomia despite having less than 30 percent of glucose values above target threshold.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3717371396">
         <span class="h3">
          Does early metformin initiation improve glycemic control and reduce need for insulin?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Usual initial GDM care (medical nutritional therapy, exercise, blood glucose monitoring) may not correct hyperglycemia as quickly as medications and thus may result in a few weeks of hyperglycemia before lack of success and need for pharmacotherapy is established. Whether initiating
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         at the time of GDM diagnosis regardless of glycemic control improves clinical outcomes compared with usual care was investigated in a randomized trial [
         <a href="#rid64">
          64
         </a>
         ]. The composite outcome (need for insulin initiation or fasting hyperglycemia ≥92 mg/dL [5.1 mmol/L] at gestational weeks 32 and 38) was not significantly different between groups, but metformin administration reduced the rate of insulin initiation (38.4 versus 52.2 percent; RR 0.75, 95% CI 0.62-0.91).
        </p>
        <p>
         Patients assigned to the
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         group had favorable trends in some secondary outcomes, but the trial was not powered to evaluate these individually:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower mean fasting glucose (at 32 weeks: 88.3 versus 90.1 mg/dL [4.9 versus 5.0 mmol/L]; at 38 weeks: 81.1 versus 84.7 mg/dL [4.5 versus 4.7 mmol/L])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less gestational weight gain from randomization to delivery (0.8 versus 2 kg)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less frequent birth weight &gt;4000 g (7.6 versus 14.8 percent) and birth weight &gt;90th centile (6.5 versus 14.9 percent)
        </p>
        <p>
        </p>
        <p>
         However, the risk for birth weight &lt;2500 g increased (6.1 versus 3.4 percent; RR 1.8, 95% CI 0.8 to 4.0) and the mean crown-heel length decreased (51.0 versus 51.7 cm; difference 0.7 cm; 95% CI -1.3 to -0.2) in the
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         group.
        </p>
        <p>
         There was no significant difference in maternal morbidity (eg, gestational hypertension or preeclampsia), need for neonatal intensive care unit (NICU) care, or neonatal hypoglycemia.
        </p>
        <p>
         Given these mixed findings, we recommend not initiating
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         at the time of GDM diagnosis except in a research setting.
        </p>
        <p class="headingAnchor" id="H2587179925">
         <span class="h2">
          Choice of pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pharmacotherapy options in pregnant patients who require pharmacotherapy are insulin (and some insulin analogs) or selected oral antihyperglycemic agents (
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         or
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         ).
        </p>
        <p>
         We favor insulin because it is effective, easily adjusted based on glucose levels, and safe for the fetus, whereas data are lacking regarding long-term outcomes of offspring exposed to oral antihyperglycemic drugs in utero. We believe that oral antihyperglycemic agents are a reasonable alternative to insulin for patients in whom pharmacotherapy is indicated but who decline to take, or are unable to comply with, insulin therapy. Our approach is generally consistent with national and international guidance [
         <a href="#rid1">
          1,24,43,65,66
         </a>
         ]. Some guidelines consider oral antihyperglycemic drugs an acceptable first-line approach in selected patients, such as those with normal fasting blood glucose levels and modest postprandial hyperglycemia [
         <a href="#rid65">
          65-67
         </a>
         ]. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p>
         Meta-analyses comparing use of oral antihyperglycemic agents with insulin therapy have generally found that both approaches can improve some pregnancy outcomes in patients with GDM or type 2 diabetes [
         <a href="#rid61">
          61,68-73
         </a>
         ]. There is a trend toward more frequent maternal hypoglycemia with use of insulin [
         <a href="#rid71">
          71
         </a>
         ], and some patients on oral agents need supplemental insulin to achieve and maintain glucose levels in the target range [
         <a href="#rid74">
          74
         </a>
         ]. However, it is difficult to draw firm conclusions about the optimal approach because of inconsistencies in criteria for GDM, glucose targets, patient adherence to treatment, clinical outcome measures across studies, and lack of long-term safety data [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         In randomized trials, compared with insulin,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced gestational weight gain (mean difference -1.31 kg, 95% CI -2.34 to -0.27) [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced birth weight (mean difference -74 g, 95% CI -115 to -33) [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced risk for macrosomia (odds ratio [OR] 0.60, 95% CI 0.45-0.79) [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced risk for neonatal hypoglycemia (risk ratio [RR] 0.63, 95% CI 0.45-0.87) [
         <a href="#rid73">
          73
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced risk for pregnancy-induced hypertension (RR 0.56, 95% CI 0.37-0.85) [
         <a href="#rid73">
          73
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased offspring body mass index (BMI, by 0.8 kg/m
         <sup>
          2
         </sup>
         ) and adiposity by mid-childhood [
         <a href="#rid75">
          75
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Differences in other outcomes were not statistically significant: large for gestational age newborn (OR 0.87, 95% CI 0.66-1.14) [
         <a href="#rid72">
          72
         </a>
         ], preterm birth (RR 1.18, 95% CI 0.67-2.07), small for gestational age newborn (RR 1.20, 95% CI 0.67-2.14), perinatal mortality (RR 0.82, 95% CI 0.17-3.92), cesarean birth (RR 0.97, 95% CI 0.80-1.19) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In randomized trials, compared with insulin,
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased mean birth weight (mean difference 290 g, 95% CI 68-511) [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased risk for macrosomia (OR 1.38, 95% CI 1.01-1.89) [
         <a href="#rid72">
          72
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased the frequency of neonatal hypoglycemia (12.2 versus 7.2 percent; difference 5.0, 95% CI 0.5-9.5) [
         <a href="#rid76">
          76
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Showed trends toward an increased risk for a large for gestational age newborn (OR 2.49, 95% CI 0.79-7.81) and less maternal gestational weight gain (mean difference -0.68 kg, 95% CI -1.69 to 0.34 kg) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Insulin
         </span>
        </p>
        <p class="headingAnchor" id="H356614524">
         <span class="h3">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The insulin dose required to achieve target glucose levels varies among individuals, but the majority of studies have reported a total dose ranging from 0.7 to 2 units per kg (current pregnant weight). Dose titration to blood glucose levels is based upon frequent self-monitoring. At least four daily glucose measurements are required (fasting and one or two hours postprandial with the addition of pre-lunch and pre-dinner measurements as needed) to optimize therapy and ensure timely dose increases as insulin requirements increase with pregnancy progression. The insulin requirement in twin gestations complicated by GDM may double with pregnancy progression.
        </p>
        <p>
         We do not use insulin pumps in patients with GDM because there are no data to suggest that they are necessary or more effective than conventional therapy, and the cost of an insulin pump is not justified over the relatively short duration of a pregnancy. However, case reports have described successful use in some pregnant people.
        </p>
        <p class="headingAnchor" id="H473573785">
         <span class="h4">
          Pragmatic approach to management of hyperglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hospitalization is not necessary to initiate insulin therapy; however, if teaching some patients the procedures they need to know is not possible in the outpatient setting, then an inpatient stay to utilize the expertise of the hospital's nursing staff may justify the cost of hospitalization.
        </p>
        <p>
         One principle we have found useful is to start with the simplest regimen and increase the complexity as needed to address the particular situation. Typically, regardless of body weight, insulin dosing is based on the glucose levels recorded in the patient's blood glucose log.
        </p>
        <p>
         The following is our general approach to management of patients diagnosed with GDM after screening at 24 to 28 weeks who have mostly postprandial hyperglycemia, fetal AC&gt;75
         <sup>
          th
         </sup>
         percentile, or EFW ≥90
         <sup>
          th
         </sup>
         percentile. Because any insulin regimen requires serial dosing adjustments in response to specific fasting or postprandial glucose levels, the starting dose should be considered just that, a starting point. Weekly glucose log review is recommended so that insulin doses can be adjusted as needed to meet target glucose levels as the pregnancy advances. Some patients may be diagnosed with diabetes and therapy initiated early in pregnancy (prior to 24 to 28 weeks screening); these patients are managed differently and generally require slightly lower insulin doses since insulin resistance is lower early in pregnancy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We begin with a single injection of 10 to 20 units of intermediate-acting basal insulin (neutral protamine Hagedorn [NPH]) and 6 to 10 units of rapid-acting insulin (lispro or aspart) in the morning immediately before breakfast; the dose within this range is based on the degree of elevation above target levels. We prefer NPH due to the peak at four to six hours after the dose, which may also aid in covering postprandial lunch excursions. Levemir can also be used but is peakless and would not help as much with the lunch post-meal peak.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If postprandial glucose levels throughout the day remain high, adjustments in the rapid-acting insulin dose are typically in the range of 10 to 20 percent. The upper end of this range is not likely to lead to hypoglycemia in patients with both obesity and GDM unless a meal is omitted after insulin is given.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If only the post-dinner glucose level remains elevated, then we add an injection of 6 to 10 units of rapid-acting insulin immediately before dinner.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If only the post-lunch glucose level remains elevated, we add an injection of 6 to 10 units of rapid-acting insulin immediately before lunch. If both post-breakfast and post-lunch glucose levels are elevated, increasing the morning NPH may be sufficient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the fasting glucose level is elevated after postprandial levels in the target range, we add an intermediate-acting basal insulin, preferably at bedtime but with dinner is another option on an individualized basis. The initial dose is 0.2 units/kg body weight.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3874478336">
         <span class="h4">
          Dosing based on glucose levels and weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         An alternative approach to insulin therapy, somewhat more complex and likely most appropriate for individuals whose glucose levels are not well managed with simpler paradigms, is described below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If only the fasting blood glucose concentration is high, an intermediate-acting basal insulin (NPH) is given before bedtime but before dinner is another option on an individualized basis; an initial dose of 0.2 unit/kg body weight is utilized. A long-acting insulin analog (
         <a class="drug drug_general" data-topicid="9023" href="/z/d/drug information/9023.html" rel="external">
          insulin glargine
         </a>
         or detemir) may be used instead [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If only postprandial blood glucose concentrations are high, 6 to 10 units of rapid-acting insulin analogs (aspart or lispro) are given immediately before meals. (See
         <a class="medical medical_review" href="/z/d/html/1752.html" rel="external">
          "General principles of insulin therapy in diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If both preprandial and postprandial blood glucose concentrations are high or if the patient's postprandial glucose levels can only be blunted when starvation ketosis occurs, then a four-injection-per-day regimen is utilized, which improved glycemic control and perinatal outcome compared with a twice-daily regimen in one randomized trial [
         <a href="#rid78">
          78
         </a>
         ], although macrosomia rates were not impacted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The starting dose is calculated by trimester of pregnancy and body weight: 0.9 units/kg in the second trimester and 1.0 units/kg in the third trimester, split into basal and bolus dosing. In patients with class II or III obesity, the initial doses of insulin may need to be increased to 1.5 to 2 units/kg to overcome the combined insulin resistance of pregnancy and obesity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two-thirds of the total daily dose is administered in the morning, with two-thirds of the morning dose given as basal insulin and one-third given as rapid-acting insulin up to 15 minutes before breakfast. One-third of the total daily dose is administered in the evening, with half of this dose given as rapid-acting insulin up to 15 minutes before dinner and the other half given as basal insulin as a nighttime dose (usually at bedtime but before dinner is another option on an individualized basis). A lunchtime dose of rapid-acting insulin may be added if there is continued postprandial lunch hyperglycemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1781222196">
         <span class="h3">
          Management of hypoglycemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypoglycemia in pregnancy is defined as a blood glucose &lt;60 mg/dL (3.3 mmol/L). Hypoglycemia remote from meal or snack time is rare in patients with GDM treated with pharmacotherapy, and it is treated by administering 10 to 20 g of a fast-acting carbohydrate snack immediately. The American Diabetes Association (ADA) suggests the following options: 4 ounces (1/2 cup) of juice or regular soda, 8 ounces (1 cup) of skim milk, or 5 to 6 hard candies (eg, Life-Savers); glucose tablets can also be used (check package for grams per tablet as content varies). Since the sugars in milk release more slowly into the bloodstream than pure sugar options, the glucose pattern seen with pure sugars (ie, rapid elevation of glucose followed by a rapid decline) may be dampened. (See
         <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">
          "Hypoglycemia in adults with diabetes mellitus", section on 'Reversing hypoglycemia'
         </a>
         .)
        </p>
        <p>
         Patients who are feeling better may recheck their blood glucose 15 to 30 minutes after treatment. If the glucose remains &lt;60 mg/dL (3.3 mmol/L), repeat treatment may be necessary. On the other hand, they may need to give themselves extra insulin to compensate for overtreatment of the symptoms.
        </p>
        <p>
         If low glucose values are encountered more than once at the same time of day, insulin doses are adjusted downward accordingly.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Type of insulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of insulin preparations of low antigenicity may minimize transplacental transfer of insulin antibodies. Human insulin is the least immunogenic of the commercially available preparations. The three rapid-acting insulin analogs (lispro, aspart, glulisine) are comparable in immunogenicity to human
         <a class="drug drug_general" data-topicid="9030" href="/z/d/drug information/9030.html" rel="external">
          regular insulin
         </a>
         , but only lispro and aspart have been investigated in pregnancy and shown to have acceptable safety profiles, minimal transfer across the placenta, and no evidence of teratogenesis. Neonatal outcomes are similar to those of patients treated with regular insulin [
         <a href="#rid61">
          61
         </a>
         ]. These two insulin analogs both improve postprandial excursions compared with human regular insulin and are associated with lower risk of delayed postprandial hypoglycemia.
        </p>
        <p>
         Long-acting insulin analogs (
         <a class="drug drug_general" data-topicid="9023" href="/z/d/drug information/9023.html" rel="external">
          insulin glargine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9022" href="/z/d/drug information/9022.html" rel="external">
          insulin detemir
         </a>
         ) have not been studied as extensively in pregnancy, but data from patients with preexisting (pregestational) diabetes and studies of placental transfer suggest that both detemir and glargine are safe and effective for use in pregnancy [
         <a href="#rid79">
          79-85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">
          "Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Type of insulin'
         </a>
         .).
        </p>
        <p>
         Based on available data, we prefer using human NPH insulin as part of a multiple injection regimen in pregnant people with GDM, especially given the peak at four to six hours after the morning dose, which can help decrease lunch postprandial blood glucose levels without an additional dose of rapid-acting insulin [
         <a href="#rid86">
          86
         </a>
         ]. The body of data support the safety and effectiveness of NPH in pregnancy, and doses can be adjusted frequently and quickly in response to changing requirements in pregnant patients.
        </p>
        <p>
         If a longer-acting insulin analog is used, we prefer detemir insulin because it can be dosed twice a day, similar to NPH, with the advantage over NPH of more consistent absorption and less variability in absorption among patients.
         <a class="drug drug_general" data-topicid="9022" href="/z/d/drug information/9022.html" rel="external">
          Insulin detemir
         </a>
         is preferred over
         <a class="drug drug_general" data-topicid="9023" href="/z/d/drug information/9023.html" rel="external">
          insulin glargine
         </a>
         because it has been studied more extensively in pregnancy and can be dosed twice per day more predictably than glargine, as previously mentioned. (See
         <a class="medical medical_review" href="/z/d/html/1752.html" rel="external">
          "General principles of insulin therapy in diabetes mellitus", section on 'Safety'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Oral hypoglycemic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         and
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         are the only noninsulin antihyperglycemic drugs used in pregnancy. Both oral hypoglycemic agents offer the advantage of significantly decreased cost compared with insulin. Metformin is not associated with hypoglycemia.
        </p>
        <p class="headingAnchor" id="H1919441034">
         <span class="h3">
          Choosing metformin versus glyburide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically important pregnancy outcomes are generally similar for
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         and
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         , with only limited evidence of benefit of one oral agent over the other.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy outcome
         </strong>
         – When compared with
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         in meta-analyses of randomized trials,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         resulted in:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar rates of perinatal mortality, neonatal hypoglycemia [
         <a href="#rid74">
          74
         </a>
         ], and hypertensive disorders of pregnancy [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower mean birth weight (mean difference -191 g, 95% CI -288 to -95 g; mean birth weight 3103 to 3360 g versus 3329 to 3463 g with
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         ) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Less macrosomia (OR 0.32, 95% CI 0.08-1.19) and large for gestational age infants (OR 0.38, 95% CI 0.18-0.78) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Less gestational weight gain (mean difference -2.22 kg, 95% CI -3.88 to -0.56 kg) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Need for supplemental insulin
         </strong>
         – The frequency of treatment failure (inability to maintain glucose levels in the target range) is similar for
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         and ranges from approximately 15 to 30 percent in most trials directly comparing the two drugs [
         <a href="#rid74">
          74,88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Placental transfer
         </strong>
         – Both drugs cross the placenta (in contrast to insulin). Fetal
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         levels are 200 percent of the maternal level and
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         levels are 70 percent of the maternal level, which has unknown long-term consequences [
         <a href="#rid89">
          89-91
         </a>
         ]. Although metformin and glyburide have not been associated with an increased risk of congenital anatomic anomalies, when either drug is prescribed, patients should be made aware that information regarding the long-term effects of transplacental passage, including possible fetal programming effects, are largely unknown, so caution is warranted until more data are available [
         <a href="#rid92">
          92-97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18999792">
         <span class="h3">
          Metformin
         </span>
         <span class="headingEndMark">
          —
         </span>
         A typical dosing regimen is to start
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         extended release (XR) 500 mg orally once daily (with dinner) and, if tolerated, increase by 500 mg (eg, 1000 mg with dinner or 500 mg with dinner plus 500 mg with breakfast) based on the degree of glucose elevations. The dose can then be increased by 500 to 1000 mg orally per week until reaching the usual effective dose of 1500 to 2000 mg orally per day divided into two doses (maximum daily dose is 2500 mg) [
         <a href="#rid98">
          98
         </a>
         ]. An immediate release preparation is also available, but we prefer the XR as it may cause fewer gastrointestinal side effects and fewer daily doses may be needed.
        </p>
        <p>
         The most common side effects of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         are gastrointestinal, including a metallic taste in the mouth, mild anorexia, nausea, abdominal discomfort, and soft bowel movements or diarrhea. These symptoms are usually mild, transient, and reversible after dose reduction or discontinuation of the drug. Symptoms can be mitigated by starting at a low dose with slow-dose escalation as needed. In a clinical trial, only 2 percent of study subjects discontinued metformin because of gastrointestinal side effects [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         The ADA recommends avoiding
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         in patients with hypertension, preeclampsia, or at risk for intrauterine growth restriction due to the potential for growth restriction or acidosis in the setting of placental insufficiency [
         <a href="#rid24">
          24,92
         </a>
         ]; however, any clinical impact of this effect has not been observed in human pregnancies. The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine do not include this caveat in their recommendations.
        </p>
        <p class="headingAnchor" id="H2071836899">
         <span class="h3">
          Glyburide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Starting doses of 2.5 to 5 mg once daily are commonly used, increased as needed to a maximum of 20 mg per day. Twice-daily dosing is often necessary to maintain glucose levels in the target range. One group that investigated
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         pharmacokinetics in pregnancy suggested pregnant patients take the drug 30 to 60 minutes before a meal, rather than with the meal, to improve efficacy [
         <a href="#rid99">
          99
         </a>
         ]. In this study, plasma glyburide concentrations in pregnant patients with GDM did not increase until one hour after drug ingestion, peaked at two to three hours, and returned to baseline by 8 to 10 hours. Thus, the drug took longer to reach peak concentration and was metabolized more rapidly than in nonpregnant females.
        </p>
        <p>
         Maternal hypoglycemia is the most common side effect, and the risk was higher than that in patients with GDM using insulin in a large trial (28.8 versus 3.5 percent; difference 25.3 percent, 95% CI 16.6-34.0) [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1765722778">
         <span class="h3">
          Patients who fail to achieve glycemic control with oral pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If oral pharmacotherapy alone does not adequately manage glucose levels, supplemental insulin can be prescribed and may be easier for the patient than switching to a multidose insulin only regimen. In contrast to nonpregnant patients, dual use of oral agents (eg,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         ) is not recommended in pregnancy because of minimal safety and efficacy data [
         <a href="#rid88">
          88
         </a>
         ] and concerns about adverse fetal effects since both drugs cross the placenta.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          INTRAPARTUM AND POSTPARTUM GLUCOSE MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intrapartum and postpartum glucose and insulin management are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4441.html" rel="external">
          "Pregestational (preexisting) and gestational diabetes: Intrapartum and postpartum glucose management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3752053252">
         <span class="h1">
          PREGNANCY MANAGEMENT AND POSTPARTUM CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obstetric management of the pregnancy and postpartum care are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">
          "Gestational diabetes mellitus: Obstetric issues and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          MATERNAL PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with GDM are normoglycemic after giving birth. However, they are at high risk for recurrent GDM and developing prediabetes (impaired glucose tolerance or impaired fasting glucose) or overt diabetes over the subsequent five years. Optimum interpregnancy care to minimize these risks has not been well-studied in randomized trials [
         <a href="#rid100">
          100
         </a>
         ]. Feasibility trials of a web-based lifestyle intervention and a telephone-based intervention reported less postpartum weight retention in patients with GDM assigned to the intervention, suggesting this type of behavioral intervention may have a favorable impact [
         <a href="#rid101">
          101,102
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         GDM in one pregnancy is a strong predictor of recurrence in a subsequent pregnancy [
         <a href="#rid103">
          103
         </a>
         ]. In a study including over 65,000 pregnancies, the frequency of GDM in the second pregnancy among patients with and without previous GDM was 41 and 4 percent, respectively [
         <a href="#rid104">
          104
         </a>
         ]. Risk factors for recurrence include high birth weight in the index pregnancy, older maternal age, high parity, high prepregnancy weight, and high weight between pregnancies [
         <a href="#rid105">
          105,106
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Long-term risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         A history of GDM is predictive of an increased risk of developing type 2 diabetes, metabolic syndrome, cardiovascular disease (CVD), and even type 1 diabetes. These risks appear to be particularly high in patients with both GDM and a hypertensive disorder of pregnancy [
         <a href="#rid107">
          107
         </a>
         ]. GDM has been called a "marker," "stress test," or "window" for future diabetes and CVD; it is not considered causal.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impaired glucose tolerance
         </strong>
         – As many as 30 percent of patients with GDM have impaired glucose tolerance during the early postpartum period [
         <a href="#rid108">
          108-110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 2 diabetes
         </strong>
         – In a meta-analysis, patients with GDM were at an almost 10-fold higher risk of developing subsequent type 2 diabetes than patients with normoglycemic pregnancies (relative risk [RR] 9.51, 95% CI 7.14-12.67; 20 studies including nearly 68,000 patients with GDM and over 1.2 million patients without GDM) [
         <a href="#rid111">
          111
         </a>
         ]. The RR was 17 within the first five years after delivery and approximately 10 after that. Absolute risks for type 2 diabetes at 1 to 5 years, &gt;5 to 10 years, and &gt;10 years postdelivery follow-up were 9, 12, and 16 percent, respectively, compared with 1 to 2 percent in the control groups. The lifetime maternal risk for diabetes has been estimated to be as high as 50
         <strong>
         </strong>
         to
         <strong>
         </strong>
         60 percent [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Waist circumference and body mass index (BMI) are the strongest anthropometric measures associated with development of type 2 diabetes in patients with GDM [
         <a href="#rid61">
          61,113
         </a>
         ], as they are in those without GDM. Type 2 diabetes develops in 50 to 75 percent of patients with obesity (BMI ≥30 kg/m
         <sup>
          2
         </sup>
         ) and a history of GDM versus fewer than 25 percent of those with GDM who achieve normal BMI after delivery [
         <a href="#rid114">
          114-116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other major risk factors are gestational requirement for insulin and early gestational age at the time of diagnosis (ie, less than 24 weeks of gestation) [
         <a href="#rid113">
          113
         </a>
         ]. Additional risk factors for impaired glucose tolerance and overt diabetes later in life include autoantibodies (eg, glutamic acid decarboxylase, insulinoma antigen-2), high-fasting blood glucose concentrations during pregnancy and early postpartum, higher-fasting plasma glucose at diagnosis of GDM and high glucose levels in the GTT, the number of abnormal values on the glucose tolerance test, neonatal hypoglycemia, and GDM in more than one pregnancy [
         <a href="#rid61">
          61,108,109,114,117-121
         </a>
         ]. In one study, an additional pregnancy increased the rate ratio of type 2 diabetes threefold compared with individuals without an additional pregnancy (RR 3.34, 95% CI 1.80-6.19) [
         <a href="#rid122">
          122
         </a>
         ]. The authors hypothesized that repeated episodes of insulin resistance contribute to the decline in beta-cell function that leads to type 2 diabetes in many high-risk individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Parity, large birth weight, and diabetes in a first-degree relative are less correlated with later diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 1 diabetes
         </strong>
         – GDM also appears to be a risk factor for the development of type 1 diabetes, particularly in populations with a high prevalence of this disorder. Specific human leukocyte antigen (HLA) alleles (DR3 or DR4) may predispose to the development of type 1 diabetes postpartum, as does the presence of islet-cell autoantibodies [
         <a href="#rid123">
          123-125
         </a>
         ] or antibodies against glutamic acid decarboxylase or insulinoma antigen 2. GDM in lean pregnant people, need for insulin treatment of GDM, diabetic ketoacidosis during pregnancy, and postpartum hyperglycemia also suggest preexisting unrecognized type 1 diabetes or high risk of developing type 1 diabetes [
         <a href="#rid125">
          125
         </a>
         ]. Although testing for antibodies is not routinely recommended, it is important for clinicians to be aware of this association.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Distinguishing type 1 from type 2 diabetes, and monogenic forms of diabetes (eg, maturity-onset diabetes of the young [MODY]) from type 1 and type 2 diabetes, is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Differentiating the cause'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">
          "Classification of diabetes mellitus and genetic diabetic syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabolic syndrome
         </strong>
         – At ≥three months postpartum, patients with GDM are more likely to have metabolic syndrome, an atherogenic lipid profile, and early vascular dysfunction than those without previous GDM [
         <a href="#rid126">
          126-129
         </a>
         ]. In one study of patients with mild GDM (ie, normal fasting glucose level on glucose tolerance test [GTT]), approximately one-third developed metabolic syndrome within 5 to 10 years after giving birth [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular disease
         </strong>
         – Patients with GDM are at higher risk of developing CVD and developing it at a younger age than those with no history of GDM [
         <a href="#rid130">
          130-133
         </a>
         ]. Even mild glucose impairment (defined as an abnormal 50 g one-hour GTT followed by a normal 100 g three-hour GTT) appears to identify individuals at increased risk of future development of CVD, usually myocardial infarction or stroke [
         <a href="#rid134">
          134
         </a>
         ]. In these studies, the increased risk was related to development of type 2 diabetes later in life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         More recent data demonstrate that the increased risk of CVD in patients with a prior history of GDM may be independent of the development of type 2 diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a pooled analysis of nine studies including over 5 million females and &gt;101,000 cardiovascular events, those with GDM had a twofold higher risk of future CVD compared with those with no history of GDM (RR 1.98, 95% CI 1.57-2.50) [
         <a href="#rid135">
          135
         </a>
         ]. Meta-regression analysis showed that the rates of incident type 2 diabetes across the studies did not affect this risk and when individuals with type 2 diabetes were excluded, GDM was still associated with an increased risk of future CVD (RR 1.56, 95% CI 1.04, 2.32).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These findings were supported by a large cohort study (Nurses' Health Study II) of individuals with a history of GDM (n &gt;6000) who had a higher crude mortality rate over 30 years follow-up than those without this history (1.74 versus 1.49 per 1000 person-years; hazard ratio [HR] 1.25, 95% CI 1.11-1.41) [
         <a href="#rid136">
          136
         </a>
         ]. The increased mortality risk was primarily due to CVD (0.14 versus 0.09 per 1000 person-years; HR 1.59; 95% CI 1.03-2.47) and persisted regardless of the subsequent development of type 2 diabetes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Follow-up
         </span>
        </p>
        <p class="headingAnchor" id="H1457610429">
         <span class="h3">
          Testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term follow-up for development of type 2 diabetes is routinely recommended for individuals with GDM, given their high risk for developing the disorder [
         <a href="#rid24">
          24,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2566599790">
         <span class="h4">
          GTT
         </span>
         <span class="headingEndMark">
          —
         </span>
         A common approach is to order a GTT to be performed 4 to 12 weeks after giving birth, using the 75 g GTT, as recommended by the American Diabetes Association (ADA) [
         <a href="#rid24">
          24
         </a>
         ]. Criteria for diagnosis of diabetes and prediabetes are shown in the tables  (
         <a class="graphic graphic_table graphicRef61853 graphicRef82479" href="/z/d/graphic/61853.html" rel="external">
          table 2A-B
         </a>
         ). Since many obstetrical providers see their patients at four to six weeks postpartum and routinely by 12 weeks, it makes sense to order the test prior to the postpartum office visit so the results are available for counseling or to provide an opportunity for scheduling/rescheduling if the test was not performed.
        </p>
        <p>
         Performing the GTT before the patient is discharged from the hospital is an alternative approach that increases adherence, which is suboptimal (&lt;50 percent) with the traditional approach. Suboptimal adherence has been attributed to not ordering the test, lack of patient follow-up for postpartum care, patient burden associated with a fasting and a two-hour laboratory procedure, and patient difficulty with childcare [
         <a href="#rid137">
          137
         </a>
         ]. There is increasing evidence that performing the test while the patient is still hospitalized after birth increases adherence to nearly 100 percent and provides reliable results [
         <a href="#rid110">
          110,138
         </a>
         ]. In an analysis of over 200 patients with GDM who completed a postpartum day two 75 g GTT, returned for a GTT at postpartum week 4 to 12, and had a A1C checked approximately one year after delivery, there were no significant differences between the day two and the 4- to 12-week postpartum GTTs in predicting impaired glucose metabolism (A1C ≥5.7 and &lt;6.5 percent) or diabetes (A1C ≥6.5 percent) at one year [
         <a href="#rid138">
          138
         </a>
         ]. At one year postpartum, the A1C was consistent with impaired glucose metabolism in 35 percent and diabetes in 4 percent of individuals tested.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effect of breastfeeding on the GTT
         </strong>
         – Breastfeeding during a two-hour 75 gram oral GTT appears to have a modest lowering effect on the two-hour glucose level (5 percent lower on average) [
         <a href="#rid139">
          139
         </a>
         ], which could affect interpretation of a borderline test. Patients should be informed in advance that they might need to repeat the test if this happens so they can make an informed decision about breastfeeding during the test versus planning the test at a time/later date when breastfeeding can be avoided. Clinicians should consider retesting those patients whose results fall within 6 mg/dL (0.4 mmol/L) of the diagnostic cut points.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2866707273">
         <span class="h4">
          Fasting glucose
         </span>
         <span class="headingEndMark">
          —
         </span>
         A fasting plasma glucose level is a reasonable alternative to the GTT but does not allow for diagnosis of impaired glucose tolerance. A glycated hemoglobin (A1C) can be performed in patients in whom obtaining a fasting specimen is especially inconvenient but performs less well for diagnosis of diabetes or prediabetes in postpartum patients because of increased peripartum red cell turnover [
         <a href="#rid140">
          140
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Diagnostic tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4098040211">
         <span class="h3">
          Counseling
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with prediabetes
         </strong>
         – Patients who meet criteria for prediabetes are counseled about their subsequent risk for developing overt diabetes and referred for discussion of management options (eg, lifestyle modification [eg, diet, physical activity, use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         ). They should try to maintain/achieve a BMI in the normal range through diet and exercise, and if possible, they should avoid medications that may adversely affect glucose tolerance (eg, glucocorticoids). They should have yearly assessment of glycemic status. Approaches to prevention of type 2 diabetes are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Prediabetes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">
          "Prevention of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Higher intensity and longer duration of breastfeeding during the first two years postpartum is associated with a reduced risk of developing type 2 diabetes in observational studies. (See
         <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">
          "Gestational diabetes mellitus: Obstetric issues and management", section on 'Breastfeeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with diabetes
         </strong>
         – Patients with overt diabetes mellitus should receive appropriate education and treatment. They should also be given advice regarding contraception and the planning of future pregnancies, especially the importance of good glycemic management prior to conception. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">
          "Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with normal test results
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk for future diabetes
         </strong>
         – Patients with a normal GTT should be counseled regarding their risk of developing GDM in subsequent pregnancies and their future risk of developing type 2 diabetes. (See
         <a class="local">
          'Recurrence'
         </a>
         above and
         <a class="local">
          'Long-term risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention of future diabetes
         </strong>
         – Patients should be informed that breastfeeding may decrease their long-term risk of developing type 2 diabetes. (See
         <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">
          "Gestational diabetes mellitus: Obstetric issues and management", section on 'Breastfeeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Lifestyle interventions are beneficial for reducing the incidence of type 2 diabetes in persons with prediabetes [
         <a href="#rid141">
          141
         </a>
         ] and these interventions (diet and exercise, achieving a normal body mass index, avoiding smoking and excessive alcohol intake) also appear to be beneficial in patients with a history of GDM, whether or not they meet criteria for prediabetes [
         <a href="#rid142">
          142
         </a>
         ]. The annual incidence of diabetes may be reduced by 30 to 50 percent or more compared with no intervention [
         <a href="#rid143">
          143,144
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Pharmacotherapy (eg,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          pioglitazone
         </a>
         ) may also have a role in preventing future type 2 diabetes. In a multicenter randomized trial, both intensive lifestyle and metformin therapy reduced the incidence of future diabetes by approximately 50 percent compared with placebo in patients with a history of GDM; metformin was much more effective than lifestyle intervention in parous patients with previous GDM [
         <a href="#rid143">
          143
         </a>
         ]. This topic is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">
          "Prevention of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Follow-up laboratory testing
         </strong>
         – Long-term follow-up is essential. Reassessment of glycemic status should be undertaken at a minimum of every three years (eg, every one to three years) [
         <a href="#rid24">
          24
         </a>
         ]. More frequent assessment may be important in patients who may become pregnant again, since early detection of diabetes is important to preconception and early prenatal care. More frequent screening (every one or two years) may also be indicated in patients with other risk factors for diabetes, such as family history of diabetes, obesity, and need for pharmacotherapy during pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The best means of follow-up testing has not been defined. The two-hour 75 g oral GTT is the more sensitive test for diagnosis of diabetes and impaired glucose tolerance in most populations, but the fasting plasma glucose is more convenient, specific, and reproducible, and less expensive. A1C is convenient and the preferred test for patients who have not fasted overnight. (See
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus", section on 'Screening tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevention of future cardiovascular disease
         </strong>
         – Given increasing evidence of an association between GDM and future CVD [
         <a href="#rid145">
          145
         </a>
         ], even in the absence of progression to type 2 diabetes, it is reasonable to discuss healthy lifestyle behaviors (eg, heart-healthy diet, maintenance of a healthy weight, tobacco avoidance, and physical activity) with all patients who have had GDM [
         <a href="#rid146">
          146
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H526370321">
         <span class="h2">
          Follow-up of patients not screened for GDM
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who did not undergo screening for GDM, but diabetes is suspected postpartum because of newborn outcome (eg, hypoglycemia, macrosomia, congenital anomalies), a postpartum GTT may be considered. A normal postpartum GTT excludes the presence of type 1 or type 2 diabetes or prediabetes; it does not exclude the possibility of GDM during pregnancy and the future risks associated with this diagnosis. Indications for screening and tests used for screening are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2006401478">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109438.html" rel="external">
          "Society guideline links: Diabetes mellitus in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2700890968">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15435.html" rel="external">
          "Patient education: Gestational diabetes (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/6735.html" rel="external">
          "Patient education: Gestational diabetes (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucose monitoring
         </strong>
         – Glucose levels are monitored several times daily in patients with
         <strong>
         </strong>
         gestational diabetes mellitus (GDM). We suggest glucose self-monitoring before breakfast and at one
         <strong>
          or
         </strong>
         at two hours after the beginning of each meal. (See
         <a class="local">
          'Glucose monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The frequency of testing may be decreased to every other day in specific patients with mild GDM (defined as no more than intermittent glucose elevations within 5 to 10 points above targets), no signs of fetal overgrowth (defined as abdominal circumference (AC) &gt;75
         <sup>
          th
         </sup>
         percentile or estimated fetal weight (EFW) ≥90
         <sup>
          th
         </sup>
         percentile), and normal amniotic fluid volume (ie, no polyhydramnios). (See
         <a class="local">
          'Can the frequency of self-monitoring be reduced?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucose targets
         </strong>
         (see
         <a class="local">
          'Glucose target'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fasting blood glucose concentration: &lt;95 mg/dL (5.3 mmol/L)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One-hour postprandial blood glucose concentration: &lt;140 mg/dL (7.8 mmol/L)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two-hour postprandial glucose concentration: &lt;120 mg/dL (6.7 mmol/L)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Benefits
         </strong>
         – A program of medical nutritional therapy, self-monitoring of blood glucose levels, and pharmacotherapy, when needed, improves some perinatal outcomes (eg, reduction of macrosomia and shoulder dystocia, and possibly preeclampsia). Moderate exercise also improves glycemic control and should be part of the treatment plan for patients with no medical or obstetric contraindications to this level of physical activity. (See
         <a class="local">
          'Rationale for treatment'
         </a>
         above and
         <a class="local">
          'Exercise'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Medical nutritional therapy
         </strong>
         – Medical nutritional therapy is the initial approach. Calories are generally divided over three meals and two to four snacks per day and are composed of approximately 40 percent carbohydrate, 20 percent protein, and 40 percent fat. Gestational weight gain recommendations are shown in the table  (
         <a class="graphic graphic_table graphicRef75820" href="/z/d/graphic/75820.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Medical nutritional therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pharmacotherapy
         </strong>
         – Pharmacotherapy is prescribed for patients who do not achieve adequate glycemic control with nutritional therapy and exercise alone (ie, at least 30 percent of glucose levels meet or exceed target thresholds within any one week)  (
         <a class="graphic graphic_algorithm graphicRef131228" href="/z/d/graphic/131228.html" rel="external">
          algorithm 1
         </a>
         ). We also suggest pharmacotherapy for patients with indirect evidence of fetal hyperinsulinemia (eg, AC &gt;75
         <sup>
          th
         </sup>
         percentile or EFW ≥90
         <sup>
          th
         </sup>
         percentile on an early third-trimester sonogram) regardless of maternal glucose levels (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Pharmacotherapy can reduce the occurrence of macrosomia and large for gestational age in newborns. (See
         <a class="local">
          'Indications for pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Insulin
         </strong>
         – We suggest prescribing insulin rather than noninsulin antihyperglycemic drugs during pregnancy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We start with the simplest insulin regimen likely to be effective based on the glucose levels recorded in the patient's blood glucose log and increase the complexity as needed. An alternative approach based on both patient weight and glucose levels is somewhat more complex and likely most appropriate for individuals whose glucose levels are not well managed with simpler paradigms. (See
         <a class="local">
          'Insulin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Oral antihyperglycemic drugs
         </strong>
         –
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         and
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         are the only oral antihyperglycemic drugs used in pregnancy and either is a reasonable alternative for patients who decline to take, or are unable to comply with, insulin therapy. The long-term effects of transplacental passage of noninsulin antihyperglycemic agents are not known. (See
         <a class="local">
          'Oral hypoglycemic agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Most patients with gestational diabetes mellitus are normoglycemic after giving birth but are at high risk for developing recurrent gestational diabetes mellitus, prediabetes (impaired glucose tolerance or impaired fasting glucose), and overt diabetes. (See
         <a class="local">
          'Recurrence'
         </a>
         above and
         <a class="local">
          'Long-term risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postpartum testing
         </strong>
         – Patients with GDM should be tested for type 2 diabetes mellitus after pregnancy  (
         <a class="graphic graphic_table graphicRef61853 graphicRef82479" href="/z/d/graphic/61853.html" rel="external">
          table 2A-B
         </a>
         ). Testing can be performed while the patient is still in the hospital after giving birth. Otherwise it is performed 4 to 12 weeks postpartum and, if results are normal, at least every three years thereafter. Lifestyle interventions (eg, achieving a healthy weight, appropriate level of physical activity/exercise) are beneficial for reducing the incidence of type 2 diabetes and related comorbidities such as cardiovascular disease (CVD). (See
         <a class="local">
          'Maternal prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2806570854">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Lois Jovanovic, MD, Donald R Coustan, MD, and Michael Greene, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Society of Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address:
           <span class="__cf_email__" data-cfemail="bbcbced9c8fbc8d6ddd695d4c9dc">
            [email protected]
           </span>
           . SMFM Statement: Pharmacological treatment of gestational diabetes. Am J Obstet Gynecol 2018; 218:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catalano PM, McIntyre HD, Cruickshank JK, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care 2012; 35:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352:2477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358:1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han S, Crowther CA, Middleton P. Interventions for pregnant women with hyperglycaemia not meeting gestational diabetes and type 2 diabetes diagnostic criteria. Cochrane Database Syst Rev 2012; 1:CD009037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durnwald CP, Mele L, Spong CY, et al. Glycemic characteristics and neonatal outcomes of women treated for mild gestational diabetes. Obstet Gynecol 2011; 117:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uvena-Celebrezze J, Fung C, Thomas AJ, et al. Relationship of neonatal body composition to maternal glucose control in women with gestational diabetes mellitus. J Matern Fetal Neonatal Med 2002; 12:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catalano PM, Thomas A, Huston-Presley L, Amini SB. Increased fetal adiposity: a very sensitive marker of abnormal in utero development. Am J Obstet Gynecol 2003; 189:1698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss JR, Crowther CA, Hiller JE, et al. Costs and consequences of treatment for mild gestational diabetes mellitus - evaluation from the ACHOIS randomised trial. BMC Pregnancy Childbirth 2007; 7:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillay J, Donovan L, Guitard S, et al. Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021; 326:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poprzeczny AJ, Louise J, Deussen AR, Dodd JM. The mediating effects of gestational diabetes on fetal growth and adiposity in women who are overweight and obese: secondary analysis of the LIMIT randomised trial. BJOG 2018; 125:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landon MB, Rice MM, Varner MW, et al. Mild gestational diabetes mellitus and long-term child health. Diabetes Care 2015; 38:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 Suppl 1:S61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez TL, Brand-Miller JC. Nutrition Therapy in Gestational Diabetes Mellitus: Time to Move Forward. Diabetes Care 2018; 41:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto JM, Kellett JE, Balsells M, et al. Gestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight. Diabetes Care 2018; 41:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han S, Middleton P, Shepherd E, et al. Different types of dietary advice for women with gestational diabetes mellitus. Cochrane Database Syst Rev 2017; 2:CD009275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez TL, Mande A, Barbour LA. Nutrition therapy within and beyond gestational diabetes. Diabetes Res Clin Pract 2018; 145:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinman RD, Pogozelski WK, Astrup A, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition 2015; 31:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jovanovic-Peterson L, Peterson CM. Dietary manipulation as a primary treatment strategy for pregnancies complicated by diabetes. J Am Coll Nutr 1990; 9:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reece EA, Hagay Z, Caseria D, et al. Do fiber-enriched diabetic diets have glucose-lowering effects in pregnancy? Am J Perinatol 1993; 10:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okesene-Gafa KA, Moore AE, Jordan V, et al. Probiotic treatment for women with gestational diabetes to improve maternal and infant health and well-being. Cochrane Database Syst Rev 2020; 6:CD012970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S282.
          </a>
         </li>
         <li class="breakAll">
          Weight Gain During Pregnancy: Reexamining the Guidelines, Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. (Ed), National Academies Press (US) 2009.
         </li>
         <li class="breakAll">
          The Art and Science of Diabetes Self-Management Education, Mensing C (Ed), American Association of Diabetes Educators, 2006. p.241.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Major CA, Henry MJ, De Veciana M, Morgan MA. The effects of carbohydrate restriction in patients with diet-controlled gestational diabetes. Obstet Gynecol 1998; 91:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson CM, Jovanovic-Peterson L. Percentage of carbohydrate and glycemic response to breakfast, lunch, and dinner in women with gestational diabetes. Diabetes 1991; 40 Suppl 2:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viana LV, Gross JL, Azevedo MJ. Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes. Diabetes Care 2014; 37:3345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng YW, Chung JH, Kurbisch-Block I, et al. Gestational weight gain and gestational diabetes mellitus: perinatal outcomes. Obstet Gynecol 2008; 112:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002; 25:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Ceysens G, Boulvain M. Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes. Cochrane Database Syst Rev 2017; 6:CD012202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laird J, McFarland KF. Fasting blood glucose levels and initiation of insulin therapy in gestational diabetes. Endocr Pract 1996; 2:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisz B, Shrim A, Homko CJ, et al. One hour versus two hours postprandial glucose measurement in gestational diabetes: a prospective study. J Perinatol 2005; 25:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moses RG, Lucas EM, Knights S. Gestational diabetes mellitus. At what time should the postprandial glucose level be monitored? Aust N Z J Obstet Gynaecol 1999; 39:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivan E, Weisz B, Homko CJ, et al. One or two hours postprandial glucose measurements: are they the same? Am J Obstet Gynecol 2001; 185:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkins JS, Casey BM, Lo JY, et al. Weekly compared with daily blood glucose monitoring in women with diet-treated gestational diabetes. Obstet Gynecol 2009; 113:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007; 30 Suppl 2:S251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendez-Figueroa H, Schuster M, Maggio L, et al. Gestational Diabetes Mellitus and Frequency of Blood Glucose Monitoring: A Randomized Controlled Trial. Obstet Gynecol 2017; 130:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raman P, Shepherd E, Dowswell T, et al. Different methods and settings for glucose monitoring for gestational diabetes during pregnancy. Cochrane Database Syst Rev 2017; 10:CD011069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofer OJ, Martis R, Alsweiler J, Crowther CA. Different intensities of glycaemic control for women with gestational diabetes mellitus. Cochrane Database Syst Rev 2023; 10:CD011624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol 2018; 131:e49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care 2011; 34:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths RJ, Vinall PS, Stickland MH, Wales JK. Haemoglobin A1c levels in normal and diabetic pregnancies. Eur J Obstet Gynecol Reprod Biol 1987; 24:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jovanovic L, Savas H, Mehta M, et al. Frequent monitoring of A1C during pregnancy as a treatment tool to guide therapy. Diabetes Care 2011; 34:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosca A, Paleari R, Dalfrà MG, et al. Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study. Clin Chem 2006; 52:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurie S, Mamet Y. Red blood cell survival and kinetics during pregnancy. Eur J Obstet Gynecol Reprod Biol 2000; 93:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunn HF, Haney DN, Kamin S, et al. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976; 57:1652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergenstal RM, Gal RL, Connor CG, et al. Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels. Ann Intern Med 2017; 167:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto ME, Villena JE. Diabetic ketoacidosis during gestational diabetes. A case report. Diabetes Res Clin Pract 2011; 93:e92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham UM, Cooke IE, McCance DR. A case of euglyacemic diabetic ketoacidosis in a patient with gestational diabetes mellitus. Obstet Med 2014; 7:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson HL, Barrett HL, Foxcroft K, et al. Prevalence of maternal urinary ketones in pregnancy in overweight and obese women. Obstet Med 2018; 11:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stehbens JA, Baker GL, Kitchell M. Outcome at ages 1, 3, and 5 years of children born to diabetic women. Am J Obstet Gynecol 1977; 127:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Churchill JA, Berendes HW, Nemore J. Neuropsychological deficits in children of diabetic mothers. A report from the Collaborative Sdy of Cerebral Palsy. Am J Obstet Gynecol 1969; 105:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzo T, Metzger BE, Burns WJ, Burns K. Correlations between antepartum maternal metabolism and intelligence of offspring. N Engl J Med 1991; 325:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naeye RL, Chez RA. Effects of maternal acetonuria and low pregnancy weight gain on children's psychomotor development. Am J Obstet Gynecol 1981; 139:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knopp RH, Magee MS, Raisys V, Benedetti T. Metabolic effects of hypocaloric diets in management of gestational diabetes. Diabetes 1991; 40 Suppl 2:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer O, Levy J, Brustman L, et al. Glycemic control in gestational diabetes mellitus--how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989; 161:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjos SL, Schaefer-Graf U, Sardesi S, et al. A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. Diabetes Care 2001; 24:1904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson WK, Wilson LM, Witkop CT, et al. Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. Evid Rep Technol Assess (Full Rep) 2008; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison RK, Cruz M, Wong A, et al. The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus. BMC Pregnancy Childbirth 2020; 20:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balsells M, García-Patterson A, Gich I, Corcoy R. Ultrasound-guided compared to conventional treatment in gestational diabetes leads to improved birthweight but more insulin treatment: systematic review and meta-analysis. Acta Obstet Gynecol Scand 2014; 93:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunne F, Newman C, Alvarez-Iglesias A, et al. Early Metformin in Gestational Diabetes: A Randomized Clinical Trial. JAMA 2023; 330:1547.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. National Collaborating Centre for Women’s and Children’s Health. February 25, 2015; NICE Guideline 3: version 2.1. https://www.nice.org.uk/guidance/ng3/chapter/1-Recommendations#gestational-diabetes-2 (Accessed on April 24, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet 2015; 131 Suppl 3:S173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper LM, Glover AV, Biggio JR, Tita A. Predicting failure of glyburide therapy in gestational diabetes. J Perinatol 2016; 36:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson W, Bolen S, Witkop CT, et al. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 2009; 113:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:457.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balsells M, García-Patterson A, Solà I, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015; 350:h102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Grzeskowiak L, Williamson K, et al. Insulin for the treatment of women with gestational diabetes. Cochrane Database Syst Rev 2017; 11:CD012037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarry-Adkins JL, Aiken CE, Ozanne SE. Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis. PLoS Med 2020; 17:e1003126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butalia S, Gutierrez L, Lodha A, et al. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabet Med 2017; 34:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown J, Martis R, Hughes B, et al. Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes. Cochrane Database Syst Rev 2017; 1:CD011967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarry-Adkins JL, Aiken CE, Ozanne SE. Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis. PLoS Med 2019; 16:e1002848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sénat MV, Affres H, Letourneau A, et al. Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. JAMA 2018; 319:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji J, He Z, Yang Z, et al. Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study. BMJ Open Diabetes Res Care 2020; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nachum Z, Ben-Shlomo I, Weiner E, Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ 1999; 319:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 2012; 35:2012.
          </a>
         </li>
         <li class="breakAll">
          Hod M, McCance DR, Ivanisevic M, et al. Perinatal Outcomes in a Randomized Trial Comparing Insulin Detemir with NPH Insulin in 310 Pregnant Women with Type 1.  Abstract 62-LB. American Diabetes Association. 71st Scientific Sessions. June 24 - 28, 2011 San Diego Convention Center - San Diego, California
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollex EK, Feig DS, Lubetsky A, et al. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care 2010; 33:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovo M, Wainstein J, Matas Z, et al. Placental transfer of the insulin analog glargine in the ex vivo perfused placental cotyledon model. Endocr Res 2011; 36:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suffecool K, Rosenn B, Niederkofler EE, et al. Insulin detemir does not cross the human placenta. Diabetes Care 2015; 38:e20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callesen NF, Damm J, Mathiesen JM, et al. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. J Matern Fetal Neonatal Med 2013; 26:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathiesen ER, Ali N, Alibegovic AC, et al. Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study. Diabetes Care 2021; 44:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jovanovic L, Pettitt DJ. Treatment with insulin and its analogs in pregnancies complicated by diabetes. Diabetes Care 2007; 30 Suppl 2:S220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalafat E, Sukur YE, Abdi A, et al. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials. Ultrasound Obstet Gynecol 2018; 52:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nachum Z, Zafran N, Salim R, et al. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care 2017; 40:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebert MF, Ma X, Naraharisetti SB, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RA, Rosenn B, Aleksa K, Koren G. Glyburide transport across the human placenta. Obstet Gynecol 2015; 125:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchghoul H, Alvarez JC, Verstuyft C, et al. Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk. PLoS One 2020; 15:e0232002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbour LA, Scifres C, Valent AM, et al. A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. Am J Obstet Gynecol 2018; 219:367.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wouldes TA, Battin M, Coat S, et al. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landi SN, Radke S, Engel SM, et al. Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. JAMA Pediatr 2019; 173:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care 2018; 6:e000456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanem LGE, Stridsklev S, Júlíusson PB, et al. Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. J Clin Endocrinol Metab 2018; 103:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbour LA, Feig DS. Metformin for Gestational Diabetes Mellitus: Progeny, Perspective, and a Personalized Approach. Diabetes Care 2019; 42:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358:2003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caritis SN, Hebert MF. A pharmacologic approach to the use of glyburide in pregnancy. Obstet Gynecol 2013; 121:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieu J, Bain E, Middleton P, Crowther CA. Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes. Cochrane Database Syst Rev 2013; :CD010211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicklas JM, Zera CA, England LJ, et al. A web-based lifestyle intervention for women with recent gestational diabetes mellitus: a randomized controlled trial. Obstet Gynecol 2014; 124:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelan S, Phipps MG, Abrams B, et al. Does behavioral intervention in pregnancy reduce postpartum weight retention? Twelve-month outcomes of the Fit for Delivery randomized trial. Am J Clin Nutr 2014; 99:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz N, Nachum Z, Green MS. The prevalence of gestational diabetes mellitus recurrence--effect of ethnicity and parity: a metaanalysis. Am J Obstet Gynecol 2015; 213:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Getahun D, Fassett MJ, Jacobsen SJ. Gestational diabetes: risk of recurrence in subsequent pregnancies. Am J Obstet Gynecol 2010; 203:467.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moses RG. The recurrence rate of gestational diabetes in subsequent pregnancies. Diabetes Care 1996; 19:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacNeill S, Dodds L, Hamilton DC, et al. Rates and risk factors for recurrence of gestational diabetes. Diabetes Care 2001; 24:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pace R, Brazeau AS, Meltzer S, et al. Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents: A Retrospective Cohort Study. Am J Epidemiol 2017; 186:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catalano PM, Vargo KM, Bernstein IM, Amini SB. Incidence and risk factors associated with abnormal postpartum glucose tolerance in women with gestational diabetes. Am J Obstet Gynecol 1991; 165:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjos SL, Buchanan TA, Greenspoon JS, et al. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months post partum. Am J Obstet Gynecol 1990; 163:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waters TP, Kim SY, Werner E, et al. Should women with gestational diabetes be screened at delivery hospitalization for type 2 diabetes? Am J Obstet Gynecol 2020; 222:73.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vounzoulaki E, Khunti K, Abner SC, et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ 2020; 369:m1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Cheng Y, Wang D, et al. Incidence Rate of Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 170,139 Women. J Diabetes Res 2020; 2020:3076463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baptiste-Roberts K, Barone BB, Gary TL, et al. Risk factors for type 2 diabetes among women with gestational diabetes: a systematic review. Am J Med 2009; 122:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dornhorst A, Bailey PC, Anyaoku V, et al. Abnormalities of glucose tolerance following gestational diabetes. Q J Med 1990; 77:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Sullivan JB. Diabetes mellitus after GDM. Diabetes 1991; 40 Suppl 2:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Sullivan JB. Body weight and subsequent diabetes mellitus. JAMA 1982; 248:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stangenberg M, Agarwal N, Rahman F, et al. Frequency of HLA genes and islet cell antibodies (ICA) and result of postpartum oral glucose tolerance tests (OGTT) in Saudi Arabian women with abnormal OGTT during pregnancy. Diabetes Res 1990; 14:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damm P, Kühl C, Bertelsen A, Mølsted-Pedersen L. Predictive factors for the development of diabetes in women with previous gestational diabetes mellitus. Am J Obstet Gynecol 1992; 167:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löbner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 2006; 55:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell C, Dodds L, Armson BA, et al. Diabetes mellitus following gestational diabetes: role of subsequent pregnancy. BJOG 2008; 115:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiersch L, Shah BR, Berger H, et al. Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus. Diabetes Care 2021; 44:1860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters RK, Kjos SL, Xiang A, Buchanan TA. Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. Lancet 1996; 347:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferber KM, Keller E, Albert ED, Ziegler AG. Predictive value of human leukocyte antigen class II typing for the development of islet autoantibodies and insulin-dependent diabetes postpartum in women with gestational diabetes. J Clin Endocrinol Metab 1999; 84:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauricio D, Balsells M, Morales J, et al. Islet cell autoimmunity in women with gestational diabetes and risk of progression to insulin-dependent diabetes mellitus. Diabetes Metab Rev 1996; 12:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Järvelä IY, Juutinen J, Koskela P, et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 2006; 29:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Retnakaran R, Qi Y, Connelly PW, et al. Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. J Clin Endocrinol Metab 2010; 95:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Retnakaran R, Qi Y, Connelly PW, et al. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. J Clin Endocrinol Metab 2010; 95:4345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heitritter SM, Solomon CG, Mitchell GF, et al. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005; 90:3983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varner MW, Rice MM, Landon MB, et al. Pregnancies After the Diagnosis of Mild Gestational Diabetes Mellitus and Risk of Cardiometabolic Disorders. Obstet Gynecol 2017; 129:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care 2008; 31:1668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr DB, Utzschneider KM, Hull RL, et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care 2006; 29:2078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessous R, Shoham-Vardi I, Pariente G, et al. An association between gestational diabetes mellitus and long-term maternal cardiovascular morbidity. Heart 2013; 99:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fadl H, Magnuson A, Östlund I, et al. Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case-control study. BJOG 2014; 121:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Retnakaran R, Shah BR. Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study. CMAJ 2009; 181:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019; 62:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang YX, Mitsunami M, Manson JE, et al. Association of Gestational Diabetes With Subsequent Long-Term Risk of Mortality. JAMA Intern Med 2023; 183:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesh KK, Khan SS, Powe CE. Gestational Diabetes and Long-Term Cardiometabolic Health. JAMA 2023; 330:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Maternal-Fetal Medicine (SMFM), Werner EF, Has P, et al. Two-day postpartum compared with 4- to 12-week postpartum glucose tolerance testing for women with gestational diabetes. Am J Obstet Gynecol 2020; 223:439.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunderson EP, Crites Y, Chiang V, et al. Influence of breastfeeding during the postpartum oral glucose tolerance test on plasma glucose and insulin. Obstet Gynecol 2012; 120:136.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence. Diabetes in pregnancy: Management from preconception to the postnatal period. Available at: https://www.nice.org.uk/guidance/ng3 (Accessed on April 16, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balk EM, Earley A, Raman G, et al. Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med 2015; 163:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang J, Qian F, Chavarro JE, et al. Modifiable risk factors and long term risk of type 2 diabetes among individuals with a history of gestational diabetes mellitus: prospective cohort study. BMJ 2022; 378:e070312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; 93:4774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bao W, Tobias DK, Bowers K, et al. Physical activity and sedentary behaviors associated with risk of progression from gestational diabetes mellitus to type 2 diabetes mellitus: a prospective cohort study. JAMA Intern Med 2014; 174:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobias DK, Stuart JJ, Li S, et al. Association of History of Gestational Diabetes With Long-term Cardiovascular Disease Risk in a Large Prospective Cohort of US Women. JAMA Intern Med 2017; 177:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunderson EP, Jaffe MG. Pregnancy and Subsequent Glucose Intolerance in Women of Childbearing Age: Heeding the Early Warning Signs for Primary Prevention of Cardiovascular Disease in Women. JAMA Intern Med 2017; 177:1742.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6790 Version 156.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29409848" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : SMFM Statement: Pharmacological treatment of gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22357187" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15951574" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18463375" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hyperglycemia and adverse pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22258997" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Interventions for pregnant women with hyperglycaemia not meeting gestational diabetes and type 2 diabetes diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422852" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Glycemic characteristics and neonatal outcomes of women treated for mild gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12683650" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Relationship of neonatal body composition to maternal glucose control in women with gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14710101" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Increased fetal adiposity: a very sensitive marker of abnormal in utero development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17963528" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Costs and consequences of treatment for mild gestational diabetes mellitus - evaluation from the ACHOIS randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34374716" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34374717" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29782075" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The mediating effects of gestational diabetes on fetal growth and adiposity in women who are overweight and obese: secondary analysis of the LIMIT randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25414152" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Mild gestational diabetes mellitus and long-term child health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18165339" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19797280" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A multicenter, randomized trial of treatment for mild gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29934477" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nutrition Therapy in Gestational Diabetes Mellitus: Time to Move Forward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29934478" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Gestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28236296" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Different types of dietary advice for women with gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29679625" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nutrition therapy within and beyond gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25287761" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2212389" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Dietary manipulation as a primary treatment strategy for pregnancies complicated by diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8397560" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Do fiber-enriched diabetic diets have glucose-lowering effects in pregnancy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32575163" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Probiotic treatment for women with gestational diabetes to improve maternal and infant health and well-being.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38078583" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38078583" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38078583" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9540949" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The effects of carbohydrate restriction in patients with diet-controlled gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1748252" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Percentage of carbohydrate and glycemic response to breakfast, lunch, and dinner in women with gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25414390" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18978100" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Gestational weight gain and gestational diabetes mellitus: perinatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11772915" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28639706" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15251512" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Fasting blood glucose levels and initiation of insulin therapy in gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15605070" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : One hour versus two hours postprandial glucose measurement in gestational diabetes: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10687763" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Gestational diabetes mellitus. At what time should the postprandial glucose level be monitored?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568785" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : One or two hours postprandial glucose measurements: are they the same?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7565999" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461427" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Weekly compared with daily blood glucose monitoring in women with diet-treated gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17596481" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28594772" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Gestational Diabetes Mellitus and Frequency of Blood Glucose Monitoring: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29081069" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Different methods and settings for glucose monitoring for gestational diabetes during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37815094" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Different intensities of glycaemic control for women with gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29370047" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21709299" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3556725" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Haemoglobin A1c levels in normal and diabetic pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20921215" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Frequent monitoring of A1C during pregnancy as a treatment tool to guide therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16601066" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11074141" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Red blood cell survival and kinetics during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/932199" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28605777" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21632139" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Diabetic ketoacidosis during gestational diabetes. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27512449" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A case of euglyacemic diabetic ketoacidosis in a patient with gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29997690" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prevalence of maternal urinary ketones in pregnancy in overweight and obese women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/835641" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Outcome at ages 1, 3, and 5 years of children born to diabetic women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4980345" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Neuropsychological deficits in children of diabetic mothers. A report from the Collaborative Sdy of Cerebral Palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1881416" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Correlations between antepartum maternal metabolism and intelligence of offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7457533" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of maternal acetonuria and low pregnancy weight gain on children's psychomotor development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1748251" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Metabolic effects of hypocaloric diets in management of gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2782347" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Glycemic control in gestational diabetes mellitus--how tight is tight enough: small for gestational age versus large for gestational age?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11679455" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18457474" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33308193" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24372329" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Ultrasound-guided compared to conventional treatment in gestational diabetes leads to improved birthweight but more insulin treatment: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37786390" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Early Metformin in Gestational Diabetes: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37786390" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Early Metformin in Gestational Diabetes: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26433807" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26796130" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Predicting failure of glyburide therapy in gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19104375" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20739011" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25609400" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29103210" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Insulin for the treatment of women with gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32442232" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27150509" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28120427" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31386659" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29715355" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32265255" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10550081" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22851598" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22851598" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19808914" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Insulin glargine safety in pregnancy: a transplacental transfer study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21226564" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Placental transfer of the insulin analog glargine in the ex vivo perfused placental cotyledon model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25614695" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Insulin detemir does not cross the human placenta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23211128" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34330786" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17596476" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Treatment with insulin and its analogs in pregnancies complicated by diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29749110" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28077460" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19295505" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25730219" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Glyburide transport across the human placenta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32379777" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29959933" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26912348" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30508164" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29682291" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29490031" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30787061" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Metformin for Gestational Diabetes Mellitus: Progeny, Perspective, and a Personalized Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18463376" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Metformin versus insulin for the treatment of gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23812467" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A pharmacologic approach to the use of glyburide in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23736989" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162257" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A web-based lifestyle intervention for women with recent gestational diabetes mellitus: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24284438" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Does behavioral intervention in pregnancy reduce postpartum weight retention? Twelve-month outcomes of the Fit for Delivery randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25757637" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : The prevalence of gestational diabetes mellitus recurrence--effect of ethnicity and parity: a metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20630491" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Gestational diabetes: risk of recurrence in subsequent pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8941462" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The recurrence rate of gestational diabetes in subsequent pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11315827" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Rates and risk factors for recurrence of gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29149255" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951553" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Incidence and risk factors associated with abnormal postpartum glucose tolerance in women with gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2375376" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months post partum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31351065" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Should women with gestational diabetes be screened at delivery hospitalization for type 2 diabetes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32404325" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32405502" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Incidence Rate of Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 170,139 Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19272478" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Risk factors for type 2 diabetes among women with gestational diabetes: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2290918" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Abnormalities of glucose tolerance following gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1748242" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Diabetes mellitus after GDM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7097963" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Body weight and subsequent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2134668" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Frequency of HLA genes and islet cell antibodies (ICA) and result of postpartum oral glucose tolerance tests (OGTT) in Saudi Arabian women with abnormal OGTT during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1530012" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Predictive factors for the development of diabetes in women with previous gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505245" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Predictors of postpartum diabetes in women with gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18081603" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Diabetes mellitus following gestational diabetes: role of subsequent pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34131049" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8551882" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10404800" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Predictive value of human leukocyte antigen class II typing for the development of islet autoantibodies and insulin-dependent diabetes postpartum in women with gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9013072" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Islet cell autoimmunity in women with gestational diabetes and risk of progression to insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505514" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19926711" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20631030" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840749" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28079773" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Pregnancies After the Diagnosis of Mild Gestational Diabetes Mellitus and Risk of Cardiometabolic Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18487472" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Increased risk of cardiovascular disease in young women following gestational diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16936156" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23749791" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : An association between gestational diabetes mellitus and long-term maternal cardiovascular morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24762194" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19703913" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30843102" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37695588" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Association of Gestational Diabetes With Subsequent Long-Term Risk of Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37561508" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Gestational Diabetes and Long-Term Cardiometabolic Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32470456" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Two-day postpartum compared with 4- to 12-week postpartum glucose tolerance testing for women with gestational diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914402" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Influence of breastfeeding during the postpartum oral glucose tolerance test on plasma glucose and insulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914402" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Influence of breastfeeding during the postpartum oral glucose tolerance test on plasma glucose and insulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26167912" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36130782" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Modifiable risk factors and long term risk of type 2 diabetes among individuals with a history of gestational diabetes mellitus: prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18826999" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24841449" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Physical activity and sedentary behaviors associated with risk of progression from gestational diabetes mellitus to type 2 diabetes mellitus: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29049820" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Association of History of Gestational Diabetes With Long-term Cardiovascular Disease Risk in a Large Prospective Cohort of US Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29049465" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Pregnancy and Subsequent Glucose Intolerance in Women of Childbearing Age: Heeding the Early Warning Signs for Primary Prevention of Cardiovascular Disease in Women.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
